ReviewCancer imaging : the official publication of the International Cancer Imaging Society2012
The role of FDG-PET/CT in gynaecological cancers.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03349463 (Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study.), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study.
Who cites it
11 citing papers in PubMed.
- From Presumed Leiomyoma to Stump: Laparoendoscopic Single-Site Hysterectomy with Contained Morcellation for a Large Unsuspected Borderline Smooth Muscle Tumor.Diagnostics (Basel, Switzerland) · 2026Article
- Comparative efficacy and workflow efficiency of integrated PET/MRI versus sequential PET/CT and MRI in gynecologic cancer staging: a prospective single-center study.Abdominal radiology (New York) · 2026Article
- Incidental endometrial cancer detected on FDG PET/CT imaging for melanoma.Radiology case reports · 2024Article
- Review
- Evaluation of a CD13 and Integrin αFrontiers in oncology · 2022Article
- The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma.Turk gogus kalp damar cerrahisi dergisi · 2021Article
- Review
- Clinical Impact ofAsia Oceania journal of nuclear medicine & biology · 2019Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2018Article
- PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.European radiology · 2015Article
- Fluorodeoxyglucose positron-emission tomography-magnetic resonance hybrid imaging: An emerging tool for staging of cancer of the uterine cervix.World journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There is now a growing body of evidence supporting the use of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in gynaecological malignancies. Although this molecular imaging technique is becoming increasingly available, PET/CT remains an expensive imaging tool. It is essential to be familiar with the circumstances in which FDG-PET/CT can add value and contribute to patient management and indeed to know when it is unlikely to be of benefit. It is also important to understand and recognize the potential pitfalls. FDG-PET/CT has been most widely adopted for staging patients with suspected advanced disease or in suspected recurrence, offering a whole-body imaging approach. However, there is great potential for this technique to act as a predictive biomarker of response to treatment, as well as a prognostic biomarker. In addition, FDG-PET images may now be incorporated into radiotherapy planning in order to refine the delineation of dose according to metabolically active sites of disease. This article reviews the literature that provides the evidence for the use of FDG-PET in gynaecological malignancies, identifies areas of real benefit and future potential, and highlights circumstances where there is limited value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.